StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a research report report published on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.
Separately, Roth Mkm reduced their price target on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 23rd.
Get Our Latest Research Report on APVO
Aptevo Therapeutics Stock Performance
Institutional Investors Weigh In On Aptevo Therapeutics
An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC bought a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 8.06% of the company’s stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Further Reading
- Five stocks we like better than Aptevo Therapeutics
- What Investors Need to Know About Upcoming IPOs
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- What is the FTSE 100 index?
- MarketBeat Week in Review – 11/18 – 11/22
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.